After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss…

Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff.

French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in…

Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech…

Gilead Sciences has unveiled the first proof-of-concept data for its novel drug candidate for nonalcoholic steatohepatitis (NASH) as it tries to rebuild…

Tonix Pharmaceuticals has started recruiting military personnel into a phase 3 trial of its drug candidate for combat-related post-traumatic stress disorder (…

Despite reports that linked Novartis to cutting back on its cell therapy work, the Swiss major says it is going full steam ahead for its CAR-T research.

Eisai’s spinoff unit H3 Biomedicine has expanded its 2015 deal with Foundation Medicine as the pair look for new cancer drivers.

Two phase 3 trials of AbbVie’s PARP inhibitor veliparib have missed their primary endpoints.

R&D